1 ate cancer versus normal prostate and benign prostatic hypertrophy.

2 carcinomas versus normal prostate and benign prostatic hypertrophy.

3   One required prostate resection for benign prostatic hypertrophy.

4 per 1000 discharges for uncomplicated benign prostatic hypertrophy.

5  smooth muscle cells in patients with benign prostatic hypertrophy.

6 latter resembling uterine leiomyomatosis and prostatic hypertrophy.

7                 The patient developed benign prostatic hypertrophy and chronic obstructive pulmonary

8 orbidity and mortality in the form of benign prostatic hypertrophy and prostate adenocarcinoma.

9  human diseases, including hirsutism, benign prostatic hypertrophy, and prostate cancer, but all avai

10 cess critical for normal development, benign prostatic hypertrophy, and tumorigenesis.

11 es of prostate cancer and 20 cases of benign prostatic hypertrophy (BPH) by immunohistochemistry and

12  a definite role in the management of benign prostatic hypertrophy, but stents must be used with caut

13 atively low (18)F-DCFBC PET uptake in benign prostatic hypertrophy lesions, compared with cancer in t

14 evels of receptor in normal glands or benign prostatic hypertrophy specimens.

15 ificantly lower (18)F-DCFBC uptake in benign prostatic hypertrophy than primary tumors (median maximu

16 l transcript was found in control and benign prostatic hypertrophy tissues.

17 wing no histological manifestation of benign prostatic hypertrophy) using in situ hybridization with